David Miller
Private Equity Investor bei Alpine Bioventures, GP, LLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mitchell Gold | M | 57 |
Alpine Bioventures, GP, LLC
 Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | 7 Jahre |
| Jay Venkatesan | M | 52 |
Alpine Bioventures, GP, LLC
Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | 9 Jahre |
| Remy Durand | M | 38 |
Alpine Bioventures, GP, LLC
Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | 6 Jahre |
| Steven Reed | M | 73 |
Curevo, Inc.
 Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | - |
| Charlie Petty | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 3 Jahre |
| George Simeone | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | - |
| Mario Barro | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 Jahre |
| Jae Uk Jeong | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 Jahre |
| Baeksik Bae | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 Jahre |
| Charles Petty | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 Jahre |
| Lisa Shelton | F | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| James Rickey | M | 45 | 7 Jahre | |
| Ryan Swanson | M | - | 4 Jahre | |
| Xiang Ming Cui | M | 55 | 5 Jahre | |
| Paul Sekhri | M | 66 | 4 Jahre | |
| Robert Conway | M | 70 | 7 Jahre | |
| R. Carruthers | M | 66 | - | |
| Stanford Peng | M | 53 | 7 Jahre | |
| James Topper | M | 62 | 8 Jahre | |
| Peter Thompson | M | 64 | 8 Jahre | |
| Jon Congleton | M | 60 | - | |
| Christopher Peetz | M | 45 | 6 Jahre | |
| Mark Litton | M | 56 | 1 Jahre | |
| Thomas Hilbert | M | - |
Western Washington University
| 3 Jahre |
| Mark Owings | M | - |
Western Washington University
| 4 Jahre |
| Randall Cooley | M | - |
Western Washington University
| 4 Jahre |
| Gregory Johnson | M | 58 |
Western Washington University
| 4 Jahre |
| Neil Powell | M | - |
Western Washington University
| 3 Jahre |
| Renae Bell | F | 57 |
Western Washington University
| 4 Jahre |
| Daniel P. Jacoy | M | - |
Western Washington University
| 3 Jahre |
| Danielle Bennett | F | - | 2 Jahre | |
| Thaedra Thullberry | F | - | 7 Jahre | |
| Daniel Tolley | M | 55 |
Western Washington University
| 4 Jahre |
| Robert Carter | M | - |
Western Washington University
| - |
| Kristine Swiderek | M | - | 3 Jahre | |
| Scott Ronk | M | - |
Western Washington University
| 4 Jahre |
| Kent Lewis | M | - |
Western Washington University
| 4 Jahre |
| Alfredo Garcia | M | 58 |
Western Washington University
| 1 Jahre |
| George P. Doyle | M | 54 |
Western Washington University
| 4 Jahre |
| Allen Muhich | M | 57 |
Western Washington University
| 4 Jahre |
| Kaylene M. Lahn | F | - |
Western Washington University
| 4 Jahre |
| Marc D. Durand | M | 58 |
Western Washington University
| 4 Jahre |
| Michael Scott Hamilton | M | - |
Western Washington University
| 2 Jahre |
| Ralph Braun | M | 57 |
Western Washington University
| 2 Jahre |
| Sean Gleason | M | - |
Western Washington University
| 4 Jahre |
| Janice Troha | F | - | - | |
| Sandra Anderson | F | - |
Western Washington University
| 4 Jahre |
| Keith Williams | M | - |
Western Washington University
| 4 Jahre |
| Todd Rawls | M | - |
Western Washington University
| 4 Jahre |
| Doug Milnor | M | - |
Western Washington University
| 4 Jahre |
| Eric Waggoner | M | - |
Western Washington University
| 4 Jahre |
| David L. Fleming | M | - |
Western Washington University
| 4 Jahre |
| Matt Beardsley | M | - |
Western Washington University
| 4 Jahre |
| Catherine Udd | F | - |
Western Washington University
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 46 | 85,19% |
| Indien | 8 | 14,81% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Miller
- Persönliches Netzwerk
